Now Playing
Opinion|Videos|August 23, 2024
Comparing Biologics and Biosimilars
Author(s)Sophia Humphreys, PharmD, MHA
Sophia Humphreys, PharmD, MHA, BCBBS, discusses the key differences between biologics and biosimilars.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What are key differences between biologics and biosimilars in terms of safety, efficacy, and FDA approval, and what sets biosimilars apart from one another?
Advertisement
Related to this article
Ataxia-telangiectasia (A-T) is a rare neurodegenerative disorder that primarily affects the nervous system, causing progressive loss of muscle control and coordination.
Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
Most patients screened by a hospital pharmacist-led transitions-of-care service had unmet pneumococcal and other vaccine needs, and most accepted vaccination when offered.
The data helps pharmaicts predict who will react strongly to mRNA vaccines—giving them a science-backed talking point during respiratory season.
CDC-recommended adult vaccination programs for pneumococcal disease, RSV, influenza, and COVID-19 prevent over 182,000 deaths and generate up to $12 in societal value for every $1 spent.
Pharmacists describe their experiences using DEA certificates for controlled substance prescribing in different practice settings, as well as barriers and opportunities for future expansion.
This article discusses a recent publication examining pharmacy access across Minnesota and explores the complex factors contributing to threatened community health access across the US.
The FDA has approved rebisufligene etisparvovec-hopf (Fayuvi), the first treatment designed to alter the course of mucopolysaccharidosis type IIIA.
Advertisement
Advertisement
Trending on Pharmacy Times
1
New Bladder Cancer Regimens Reshape Treatment Across Disease Stages
2
FDA Approves Rebisufligene Etisparvovec as First Gene Therapy for Children With Sanfilippo Syndrome Type A
3
Radioligand Therapy Doesn’t Need to Be Risk-Free—It Needs to Be Worth It
4
Biologic Stewardship: The Next Frontier for Health System Pharmacists
5